Alzheimer's disease treatment and methods
AssigneePharmzandia Corporation
InventorPeter Butzloff
Life of this patent
Estimating the term…
Loading patent…
AssigneePharmzandia Corporation
InventorPeter Butzloff
Estimating the term…
A nanoparticle composed of buckminsterfullerene bonded to glutamine, gamma amino butyric acid (GABA) and adenosine triphosphate is provided. This nanoparticle helps to regulate the energy metabolism, neural excitability, and signal transduction within the synapse and between the astrocytes and the neuronal networks of the human brain when these become dysfunctional. It is intended as a treatment for Alzheimer's disease, Lewy Body disease and other neuropathological diseases of the glutamine-glutamate-GABA cycle. Utility for remediating comorbid sexual dysfunction is promoted, as well as the antioxidant and protein oligomer disassembly properties. The adenosine triphosphate adduct provides a reversible inorganic phosphate energy storage and supply, the glutamine adduct provides a stable reservoir of this amino acid that is resistant to breakdown by reactive oxygen species, reactive nitrogen species, and astrocytes. The GABA and buckminsterfullerene functional groups are anti-oxidants to treat the most oxidatively stressed regions at neural structures.
A nanoparticle compound comprising:
A method of curing, treating, or prophylactically avoiding sexual dysfunction in a subject, comprising the step of:
A method of curing, treating, or prophylactically avoiding Alzheimer's disease or Lewy Body Disease and some types of brain dysfunction in Autism in a subject, comprising the step of:
A method of making a compound including buckminsterfullerene C60 bonded to a glutamine, a gamma amino butyric acid, and also bonded to an adenosine phosphate functional group, the method comprising:
Dependencies are inferred from the claim text.